Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAL ER dose-ranging study for cough in idiopathic pulmonary fibrosis
NL-OMON58873Phase 2Completed
- Sponsor
- Trevi Therapeutics
- Start
- Feb 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nalbuphine in idiopathic pulmonary fibrosis (IPF), sponsored by Trevi Therapeutics. Started Feb 2024; status: completed.
02
Drugs
nalbuphine
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON58873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58873.